SHANGHAI, China, May 21 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:
WX), a leading pharmaceutical, biotechnology and medical device research
and development outsourcing company with operations in China and the United
States, is proud to announce that the distinguished Stanford University
Professor Barry M. Trost ( http://www.stanford.edu/group/bmtrost/ ) has
visited WuXi PharmaTech and given two seminars on May 19 and 20.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )
Dr. Barry M. Trost, Tamaki Professor of Humanities and Sciences in the
chemistry department at Stanford University, is a world renowned organic
chemist and a fellow of the U.S. National Academy of Sciences. Professor
Barry M. Trost's professional interests include asymmetric allylic
alkylation and efficient enantioselective synthesis. He has made great
contributions to the modern synthetic organic chemistry and green
chemistry. Many widely used chemistry reactions, such as the Trost
asymmetric allylic alkylation, Tsuji-Trost reaction and the Trost ligand,
are named after him.
Professor Trost studied at the University of Pennsylvania and received
his Ph.D. from the Massachusetts Institute of Technology in 1965. He was a
professor at the University of Wisconsin-Madison from 1965 until his
appointment to Stanford University in 1987. Professor Trost has more than
820 scientific publications, over 320 lectures at various national and
international meetings, and over 40 worldwide awards and honors.
As another luminary speaker of WuXi PharmaTech Science Seminar Series,
Professor Trost gave the WuXi scientists two lectures titled "New Synthetic
Strategies to Bioactive Products" and "On Inventing Reactions for Atom
Economy." Professor Trost captivated the audience from beginning to end
during the lectures and answered questions from the packed crowd.
"This is my first time to give a lecture to a pharmaceutical service
company in China. I am very impressed by WuXi's Science Seminar Series
program as well as the research capability and scientific acumen of WuXi's
young scientists. Talents are absolutely the key to success for any
business, especially for WuXi which provides high quality research and
development services to global life science companies," commented Professor
Barry M. Trost.
"We are very privileged to have Dr. Trost share his brilliant expertise
with our young scientists," commented Dr. Ge Li, Chairman and Chief
Executive Officer of WuXi PharmaTech. "As we broaden our R&D service scope
our success very much depends on the quality of our scientists. Investing
in people is and will continue to be one of our top strategies."
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical
device R&D outsourcing company, with operations in China and the United
States. As a research-driven and customer-focused company, WuXi PharmaTech
provides pharmaceutical, biotechnology and medical device companies a broad
and integrated portfolio of laboratory and manufacturing services
throughout the drug and medical device R&D process. WuXi PharmaTech's
services are designed to assist its global partners in shortening the cycle
and lowering the cost of drug and medical device R&D. For more information,
please visit: http://www.wuxipharmatech.com .
For more information, please contact:
SOURCE WuXi PharmaTech